glp 1 receptor agonist for weight loss GLP1 Agonists—Effects beyond Obesity and Diabetes GLP-1RAs Reduce External Eating Behavior

Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT

Injectable semaglutide was started at 0.25 mg once weekly Even though JMs A1C is fairly well controlled (7.1%), he has established ASCVD

In obesity treatment, the hierarchy of outcomes is reversed

Mazzolai L, Teixido-Tura G, Lanzi S, et al

Additionally, the nuclear transcription factor (Foxo1) is phosphorylated upon activation of phosphoinositide- 3-kinaseprotein kinase B/Akt (PI3 K-PKB/Akt), which in turn deactivates molecules to restrict the activity of proapoptotic pathways [66]

Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide